Discover the latest insights from the FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU). This comprehensive document provides a clarified framework for pharmaceutical companies to share scientifically sound information with healthcare providers. In this article, our EVERSANA ONCOLOGY experts explore how to align strategy with compliance while maximizing the impact of data across a variety of scientifically sound sources.
Download the full article to explore:
- New Flexibility for Field Personnel: Learn about the expanded opportunities for proactive scientific exchange and the necessary compliance measures.
- Key Updates from the Guidance: Understand the resolved ambiguities and new requirements for sharing scientific information.
- Practical Implementation Tips: Get actionable advice on maintaining compliance while engaging in scientific dialogue.
- Confident and Compliant Communication: Discover how to share credible, science-based information without crossing promotional lines.
Unlock valuable knowledge and stay ahead in the pharmaceutical industry—download the complete article now!
Author
Anne Marie is helping EVERSANA deliver value to stakeholders across the life sciences industry. Through her multi-decade career at prominent large and small pharmaceutical companies, she has become a proven biopharma leader driving cross-functional…
Tim has served as a strategic lead to healthcare companies for more than 25 years in advertising, marketing, and finance roles in agency and client settings. His work spans pre-clinical to sunset strategies and from brand infrastructure to digital roadmaps. He has helped stand up clinical trial…
Susan leads field medical efforts for EVERSANA. As a leader in the life sciences industry, she brings more than 20 years of medical affairs experience across multiple therapeutic areas, including oncology, hepatology and rare…